Baader Helvea downgraded Newron Pharma to Add from Buy with a price target of CHF 7.20, up from CHF 2.60. The analyst updated the model to account for evenamide’s recent success in the open-label trial in treatment-resistant schizophrenia. It cites valuation for the downgrade.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly